Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis Heart Pill Aces Major Test

by Lisa M. Jarvis
September 8, 2014 | A version of this story appeared in Volume 92, Issue 36

Novartis’s heart-failure drug LCZ696 handily beat the standard of care, enalapril, in a large Phase III study. LCZ696, which combines the approved angiotensin II receptor antagonist valsartan with the experimental neprilysin inhibitor sacubitril, reduced the risk of cardiovascular death or hospitalization by 20% in people with systolic heart failure. On the basis of the study results, Leerink Partners stock analyst Seamus Fernandez doubled his 2026 sales forecast for the drug to $6.4 billion. Novartis plans to file for FDA approval before the end of the year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.